Abstract
In 2023, the IARC identifies 25 certain carcinogens (and exposure situations) (IARC group 1) for which there is an excess of bronchopulmonary cancer in occupational settings. Several of these certain carcinogens are classified in France as an occupational disease. However, a number of agents frequently encountered in the workplace are not recognized as an occupational disease in France. In the specific case of asbestos, the FIVA (Fonds d’indemnisation des victimes de l’amiante) provides additional compensation for the damage suffered, beyond that granted by recognition as an occupational disease. In the clinical management of pneumology patients, it is important to identify any exposure to carcinogenic agents. Recognition of lung cancer as an occupational disease is a major medical and social issue for patients. Several approaches can be used to identify exposure to occupational carcinogens: occupational interview (with specific questionnaires or self-questionnaires), biometrological analysis for certain agents, or imaging. Once an occupational exposure has been identified, the clinician may or may not advise the patient to file an occupational disease claim.1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call